Table 3

Site-specific cancer incidence by treatment group (through February 1, 1996)

Cancer	Cases			Unadjusted^a					Adjusted^b
Cancer		Se	Placebo	RR	95% CI	P	HR	95% CI	P
All sites	105	137	0.75	0.58–0.98	0.03	0.75	0.58–0.97	0.03
Prostate	22	42	0.51	0.29–0.87	0.009	0.48	0.28–0.80	0.005
Lung	25	35	0.70	0.40–1.21	0.18	0.74	0.44–1.24	0.26
Colorectal	9	19	0.46	0.19–1.08	0.055	0.46	0.21–1.02	0.057
Other carcinomas	6	9	0.66	0.19–2.07	0.44	0.67	0.24–1.88	0.44
Other noncarcinomas	3	5	0.59	0.09–3.04	0.50	0.59	0.14–2.47	0.47
Esophageal	2	5	0.39	0.04–2.41	0.28	0.40	0.08–2.07	0.28
Melanoma	11	9	1.21	0.46–3.30	0.68	1.18	0.49–2.85	0.71
Bladder	10	8	1.24	0.44–3.61	0.66	1.28	0.50–3.25	0.60
Breast	11	6	1.82	0.62–6.01	0.24	1.89	0.69–5.14	0.21
Head and neck	9	7	1.27	0.42–4.01	0.65	1.27	0.47–3.42	0.63
Lymphoma and leukemia	8	6	1.32	0.40–4.61	0.62	1.25	0.43–3.61	0.68
Cancer mortality, all sites	40	66	0.59	0.39–0.89	0.008	0.59	0.39–0.87	0.008

^a RR and 95% CI were derived from incidence rate ratios, and Ps were derived from log-rank tests.
^b 95% CI and Ps were derived from the Cox proportional hazards model adjusted for age (continuous), gender, and smoking (never, former, current) at randomization.